Patricia Buchanan, MD
Family Medicine · Eugene, ORNPI 1487768859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,438 and has fallen 88.2% since, to $169 in 2025. Among family medicine clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$492
- Pfizer$373
- Amgen$303
- AbbVie$192
- Novartis$166
- Bristol Myers Squibb$136
- plus $1K from 22 others
Across 34 payments — averaging $6939.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vivus LLC$96K
- GSK$73K
- Sanofi US Services Inc.$31K
- Pfizer$27K
- Lexicon Pharmaceuticals, Inc.$8K
- Merck$1K
What the payments were for
- Food & beverage$2,789100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $492 |
| Pfizer | 26 | $373 |
| Amgen | 16 | $303 |
| AbbVie(2 entities) | 10 | $192 |
| Novartis | 9 | $166 |
| Bristol Myers Squibb | 7 | $136 |
| GSK | 6 | $119 |
| E.r. Squibb & Sons, L.L.C. | 15 | $118 |
| Novo Nordisk | 7 | $114 |
| Lilly USA, LLC | 7 | $113 |
| Johnson & Johnson(2 entities) | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 5 | $70 |
| Boehringer Ingelheim | 5 | $69 |
| Exact Sciences | 3 | $69 |
| Amarin Pharma, Inc. | 3 | $63 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Abbott | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Merck | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Philips North America LLC | 1 | $11 |
How this compares
$2,795 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 210 | $209,460 |
| TrulicityDulaglutide | 79 | $85,662 |
| OzempicSemaglutide | 78 | $85,147 |
| XareltoRivaroxaban | 26 | $42,869 |
| JardianceEmpagliflozin | 36 | $39,926 |
| Bydureon BciseExenatide Microspheres | 32 | $34,984 |
| MounjaroTirzepatide | 26 | $31,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,569 |
| MyrbetriqMirabegron | 22 | $20,434 |
| Spiriva HandihalerTiotropium Bromide | 28 | $17,470 |
| FarxigaDapagliflozin Propanediol | 11 | $13,552 |
| EntrestoSacubitril/Valsartan | 16 | $12,444 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,359 |
| CreonLipase/Protease/Amylase | 11 | $10,450 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $373 | $209,460210 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $113 | $117,429105 claims |
| Novo NordiskOzempic | $114 | $85,14778 claims |
| Johnson & JohnsonXarelto | $72 | $42,86926 claims |
| Boehringer IngelheimJardiance | $69 | $39,92636 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $119 | $28,73040 claims |
| AstraZenecaFarxiga, Symbicort | $492 | $24,91148 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $20,43422 claims |
| NovartisEntresto | $166 | $12,44416 claims |
| AbbVieCreon | $192 | $10,45011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Eugene
- Hylke SniederEugene$6K
- Randy ReeseEugene$5K
- David KobliskaEugene$4K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.